Maura Sonego
Overview
Explore the profile of Maura Sonego including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nespolo A, Stefenatti L, Pellarin I, Gambelli A, Rampioni Vinciguerra G, Karimbayli J, et al.
Sci Adv
. 2024 Nov;
10(46):eadp6567.
PMID: 39536107
PARP inhibitors (PARPi) represent a game-changing treatment for patients with ovarian cancer with tumors deficient for the homologous recombination (HR) pathway treated with platinum (Pt)-based therapy. PARPi exert their cytotoxic...
2.
Gambelli A, Nespolo A, Rampioni Vinciguerra G, Pivetta E, Pellarin I, Nicoloso M, et al.
EMBO Mol Med
. 2024 Jul;
16(8):1981.
PMID: 38997596
No abstract available.
3.
Gambelli A, Nespolo A, Rampioni Vinciguerra G, Pivetta E, Pellarin I, Nicoloso M, et al.
EMBO Mol Med
. 2024 Apr;
16(5):1162-1192.
PMID: 38658801
Platinum (PT)-resistant Epithelial Ovarian Cancer (EOC) grows as a metastatic disease, disseminating in the abdomen and pelvis. Very few options are available for PT-resistant EOC patients, and little is known...
4.
De Marco C, Sonego M, Battaglia A, Viglietto G, Biamonte F
Front Oncol
. 2022 Nov;
12:1062921.
PMID: 36387111
No abstract available.
5.
Rampioni Vinciguerra G, Sonego M, Segatto I, DallAcqua A, Vecchione A, Baldassarre G, et al.
Front Oncol
. 2022 Jun;
12:891580.
PMID: 35712501
The cyclin D-CDK4/6 complexes play a pivotal role in controlling the cell cycle. Deregulation in cyclin D-CDK4/6 pathway has been described in many types of cancer and it invariably leads...
6.
Lombardi R, Sonego M, Pucci B, Addi L, Iannelli F, Capone F, et al.
Mol Oncol
. 2020 Dec;
15(4):1005-1023.
PMID: 33331136
Acquired resistance to platinum (Pt)-based therapies is an urgent unmet need in the management of epithelial ovarian cancer (EOC) patients. Here, we characterized by an unbiased proteomics method three isogenic...
7.
Viotto D, Russo F, Anania I, Segatto I, Rampioni Vinciguerra G, DallAcqua A, et al.
J Pathol
. 2020 Nov;
253(2):234-245.
PMID: 33140857
The CDKN1B gene, encoding for the CDK inhibitor p27 , is mutated in defined human cancer subtypes, including breast, prostate carcinomas and small intestine neuroendocrine tumors. Lessons learned from small...
8.
Ranzuglia V, Lorenzon I, Pellarin I, Sonego M, DallAcqua A, DAndrea S, et al.
Oncogene
. 2020 Aug;
39(40):6370-6386.
PMID: 32848212
For many tumor types chemotherapy still represents the therapy of choice and many standard treatments are based on the use of platinum (PT) drugs. However, de novo or acquired resistance...
9.
10.
Pellarin I, DallAcqua A, Gambelli A, Pellizzari I, DAndrea S, Sonego M, et al.
Oncogene
. 2020 Apr;
39(22):4390-4403.
PMID: 32332923
In epithelial ovarian cancer (EOC), response to platinum (PT)-based chemotherapy dictates subsequent treatments and predicts patients' prognosis. Alternative splicing is often deregulated in human cancers and can be altered by...